David A. Foster to Drug Resistance, Neoplasm
This is a "connection" page, showing publications David A. Foster has written about Drug Resistance, Neoplasm.
Connection Strength
1.141
-
Utter M, Chakraborty S, Goren L, Feuser L, Zhu YS, Foster DA. Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes. Cancer Lett. 2018 06 01; 423:28-35.
Score: 0.562
-
Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene. 2003 Jun 19; 22(25):3937-42.
Score: 0.203
-
Chakraborty S, Utter MB, Frias MA, Foster DA. Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin. Cancer Lett. 2021 12 01; 522:164-170.
Score: 0.180
-
Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA. The Enigma of Rapamycin Dosage. Mol Cancer Ther. 2016 Mar; 15(3):347-53.
Score: 0.122
-
Foster DA. Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. Expert Rev Anticancer Ther. 2004 Aug; 4(4):691-701.
Score: 0.055
-
Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res. 2009 Dec 01; 69(23):9056-64.
Score: 0.020